CNBG Covid 19 Vaccine is a safe vaccine developed by Beijing Institute of Biologic Products and China National Biotech Group (CNBG) unit. Researchers have approved this vaccine and proven to trigger immunity response during initial and mid-stage test in humans. The vaccine- BBIBP-CorV is approved for an emergency inoculation programme in China. It will be provided to professional working at frontline and are at high risk of infection.
The World Health Organization (WHO) also recognized BBIBP-CorV as one of ten global coronavirus vaccine programmes which have entered the Phase III of trials trials. The four coronavirus vaccine programmes are led by Chinese scientists. In the phase I and II trials of BBIBP-CorV, more than 600 healthy people aged between 18 and 80 years participated. The Covid-19 vaccine trial was carried out from 29 April to 30 July in a single centre in China. Based on the trial reports, participants well-tolerated two injections of BBIBP-CorV at three different doses. The vaccine recipients showed humoral immune response during the trial. The antibodies levels in recipients aged 60 and above took longer to increase in comparison to younger recipients.